TAK-360 Extension Study for Narcolepsy or Excessive Sleepiness
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This is a follow-up study for people who already completed a TAK-360 trial for narcolepsy (a sleep disorder causing sudden sleep attacks) or idiopathic hypersomnia (excessive daytime sleepiness). Researchers want to see if continuing TAK-360 remains safe and effective for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have narcolepsy type 1 or 2, or idiopathic hypersomnia (confirmed by a doctor)
- You must have already completed the main TAK-360 trial that led to this follow-up study
- You must be willing to follow all study procedures and visit requirements
- You cannot be pregnant, planning to become pregnant, or breastfeeding
- You must not have any new serious health conditions (heart disease, stroke, seizures, cancer, thyroid disease, liver disease) since you finished the parent trial
- You must not have had a recent head injury, gastrointestinal disease affecting drug absorption, or thoughts of harming yourself
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called TAK-360 for people with narcolepsy type 2 (narcolepsy without cataplexy). It aims to see if the drug safely reduces daytime sleepiness.
This study tests a new medication called TAK-360 to help adults with narcolepsy type 1 (a condition that causes extreme daytime sleepiness and sudden muscle weakness called cataplexy) feel more alert during the day. The goal is to see if this treatment is safe and effective for managing narcolepsy symptoms.
This Phase 2/3 study tests TAK-861 in people with narcolepsy type 1 (NT1) who already completed an earlier TAK-861 trial. The goal is to see if the medicine remains safe and effective for ongoing central (brain-related) sleepiness problems.
This study tests an investigational medication called TAK-360 for people with idiopathic hypersomnia (IH), a sleep disorder that causes excessive daytime sleepiness. The goal is to see if the drug can help reduce sleepiness and improve daily function.
This study tests a new medication, ALKS 2680, to see if it helps reduce daytime sleepiness and other symptoms in adults with narcolepsy type 1. It may offer a new treatment option for people with this condition.
This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.
Hear when a new Idiopathic Hypersomnia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.